Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ImmuCell Corp ICCC

Healthcare Biotechnology
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which... see more

Recent & Breaking News (NDAQ:ICCC)

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024

GlobeNewswire 10 days ago

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

GlobeNewswire February 27, 2024

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

GlobeNewswire February 16, 2024

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023

GlobeNewswire January 8, 2024

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023

GlobeNewswire November 13, 2023

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

GlobeNewswire November 7, 2023

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023

GlobeNewswire October 5, 2023

ImmuCell Announces Submission of CMC Technical Section to the FDA

GlobeNewswire August 29, 2023

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023

GlobeNewswire August 10, 2023

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023

GlobeNewswire August 7, 2023

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023

GlobeNewswire July 11, 2023

ImmuCell Announces Change in Timing of Anticipated FDA Submission

GlobeNewswire June 28, 2023

ImmuCell Appoints Bryan K. Gathagan to Board of Directors

GlobeNewswire June 21, 2023

ImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility

GlobeNewswire June 15, 2023

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

GlobeNewswire May 16, 2023

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023

GlobeNewswire May 11, 2023

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023

GlobeNewswire May 4, 2023

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023

GlobeNewswire April 5, 2023

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022

GlobeNewswire February 21, 2023

ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022

GlobeNewswire February 15, 2023